Invention Grant
- Patent Title: Predicting responders to cyclophosphamide therapy
-
Application No.: US16614883Application Date: 2018-05-18
-
Publication No.: US11573234B2Publication Date: 2023-02-07
- Inventor: Magdalena Plebanski , Mutsa Tatenda Madondo
- Applicant: Royal Melbourne Institute of Technology
- Applicant Address: AU Melbourne
- Assignee: Royal Melbourne Institute of Technology
- Current Assignee: Royal Melbourne Institute of Technology
- Current Assignee Address: AU Melbourne
- Agency: Storella & Witt, LLP
- Priority: AU2017901908 20170519
- International Application: PCT/AU2018/050478 WO 20180518
- International Announcement: WO2018/209404 WO 20181122
- Main IPC: G01N33/53
- IPC: G01N33/53 ; G01N33/574 ; C07K16/28 ; G01N33/50 ; A61K31/675
Abstract:
The present disclosure is based on detecting CC chemokine receptor 4 (CCR4) expression on T effector cells to diagnostically or prophylactically predict subjects, in particular those with a gynaecological cancer who will respond to treatment with low dose cyclophosphamide.
Public/Granted literature
- US20200158733A1 Predicting Responders to Cyclophosphamide Therapy Public/Granted day:2020-05-21
Information query
IPC分类:
